))
Episode 18. Management of Smoldering Multiple Myeloma
Manage episode 358797279 series 3369804
Content provided by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
1. How I Approach Smoldering Myeloma (Vaxman and Gertz):
https://ashpublications.org/blood/article/140/8/828/485274
2. Risk-Stratification Models in SMM:
Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/
PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/
PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/
IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/
3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):
https://pubmed.ncbi.nlm.nih.gov/36067617/
4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):
https://pubmed.ncbi.nlm.nih.gov/31652094/
5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:
GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268
ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739
6. Current Clinical Trial Landscape in Smoldering Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34114943/
7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?
47 episoade
Distribuie
